Company profile
PRAXIS PRECISION MEDICINES, INC.
NASDAQ:PRAXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RELUTRIGINE | phase2_3 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (16)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07010471 | phase3 | active_not_recruiting | 2025-07-09 | 2026-12-01 | Praxis Precision Medicines | A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine |
| NCT05021991 | phase2 | completed | 2021-10-14 | 2023-02-09 | Praxis Precision Medicines | A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor |
| NCT04969510 | phase2 | completed | 2021-06-24 | 2022-07-15 | Praxis Precision Medicines | A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder |
| NCT07019922 | phase3 | recruiting | 2025-08-13 | 2026-12-01 | Praxis Precision Medicines | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety |
| NCT05387642 | phase2 | withdrawn | 2022-04-05 | 2022-06-30 | Praxis Precision Medicines | A Clinical Trial of PRAX-114 in Participants With Essential Tremor |
FDA applications (0)
No records yet.